Published in Gut Liver on October 18, 2012
Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis. J Korean Med Sci (2015) 0.80
Helicobacter pylori: evidence-based review with a focus on immigrant populations. J Gen Intern Med (2013) 0.78
Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication. World J Gastroenterol (2015) 0.77
Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract (2015) 0.75
Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease. Gut Liver (2017) 0.75
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Seroprevalence of Helicobacter pylori in South Korea. Helicobacter (2007) 2.21
Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother (1999) 1.80
Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther (2000) 1.73
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther (2003) 1.59
High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther (2003) 1.57
Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol (2004) 1.47
Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol (2010) 1.36
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.24
Eradication of Helicobacter pylori: a clinical update. MedGenMed (2004) 1.20
Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther (2002) 1.10
Rifaximin: in vitro and in vivo antibacterial activity--a review. Chemotherapy (2005) 1.10
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis (2003) 1.09
'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter (2003) 1.06
Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis (2000) 1.03
The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology (2011) 1.02
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis (2003) 1.01
Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol (2002) 0.99
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther (2005) 0.97
Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther (2006) 0.96
[The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years]. Korean J Gastroenterol (2006) 0.96
[Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol (2011) 0.92
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea]. Korean J Gastroenterol (2011) 0.91
[The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication]. Korean J Gastroenterol (2006) 0.91
[The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy]. Korean J Gastroenterol (2010) 0.91
[Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication]. Korean J Gastroenterol (2007) 0.89
Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol (2005) 0.85
In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol (2000) 0.85
[Inter-departmental differences in the eradication therapy for Helicobacter pylori infection: a single center study]. Korean J Gastroenterol (2009) 0.84
Treatment of H. pylori infection: a review. Curr Med Chem (2005) 0.83
The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother (1995) 0.83
Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis (2006) 0.81
Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter (2011) 0.81
Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion (2006) 0.80
[Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication]. Korean J Gastroenterol (2008) 0.80
Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis (2004) 0.79
In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis (1994) 0.77
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol (2012) 2.43
A survey of Enterobius vermicularis infection among children on western and southern coastal islands of the Republic of Korea. Korean J Parasitol (2005) 1.70
Influence of endothelial nitric oxide synthase gene polymorphisms (-786T>C, 4a4b, 894G>T) in Korean patients with coronary artery disease. Thromb Res (2006) 1.63
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Heat-stable enterotoxin of Escherichia coli (STa) can stimulate duodenal HCO3(-) secretion via a novel GC-C- and CFTR-independent pathway. FASEB J (2007) 1.46
[Factors associated with liver stiffness in chronic liver disease]. Korean J Hepatol (2009) 1.44
Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. Liver Int (2010) 1.43
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology (2007) 1.33
Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol (2004) 1.32
Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene (2012) 1.30
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology (2011) 1.29
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology (2007) 1.21
Bowel obstruction caused by an intramural duodenal hematoma: a case report of endoscopic incision and drainage. J Korean Med Sci (2009) 1.21
HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun (2007) 1.18
Unusual complications related to endoscopic retrograde cholangiopancreatography and its endoscopic treatment. Clin Endosc (2013) 1.17
Association of the miR-146aC>G, miR-149T>C, miR-196a2T>C, and miR-499A>G polymorphisms with gastric cancer risk and survival in the Korean population. Mol Carcinog (2012) 1.13
Plagiorchis muris infection in Apodemus agrarius from northern Gyeonggi-do (Province) near the demilitarized zone. Korean J Parasitol (2007) 1.11
Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver (2012) 1.08
Gender-specific protection of estrogen against gastric acid-induced duodenal injury: stimulation of duodenal mucosal bicarbonate secretion. Endocrinology (2008) 1.05
Apodemus agrarius as a new definitive host for Neodiplostomum seoulense. Korean J Parasitol (2007) 1.04
Atypical manifestations of hepatitis A infection: a prospective, multicenter study in Korea. J Med Virol (2010) 1.02
Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene (2013) 1.01
Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. Dig Dis Sci (2010) 0.99
Gender-specific association of the VEGF -2578C > A polymorphism in Korean patients with colon cancer. Anticancer Res (2007) 0.96
Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea. Anticancer Res (2008) 0.95
Angular positioning of stent increases bowel perforation after self-expandable metal stent placement for malignant colorectal obstruction. Clin Endosc (2013) 0.95
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol (2013) 0.94
Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population. Anticancer Res (2005) 0.94
Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans. Mol Carcinog (2012) 0.92
Endoscopic resection of giant colonic lipoma: case series with partial resection. Clin Endosc (2013) 0.91
[The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication]. Korean J Gastroenterol (2006) 0.91
Functional self-expandable metal stents in biliary obstruction. Clin Endosc (2013) 0.91
P2Y receptors mediate Ca2+ signaling in duodenocytes and contribute to duodenal mucosal bicarbonate secretion. Am J Physiol Gastrointest Liver Physiol (2008) 0.89
Deglutition syncope associated with ventricular asystole in a patient with permanent atrial fibrillation. Korean Circ J (2010) 0.88
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine (2012) 0.88
Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene polymorphisms as risk factors for hepatocellular carcinoma in a Korean population. Anticancer Res (2008) 0.87
Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol (2007) 0.87
Asymmetry analysis of the retinal nerve fiber layer thickness in normal eyes using optical coherence tomography. Korean J Ophthalmol (2005) 0.87
Acute hepatitis C in Korea: different modes of infection, high rate of spontaneous recovery, and low rate of seroconversion. J Med Virol (2011) 0.87
Implantable cardioverter-defibrillator implantation in a patient with atrial standstill. Yonsei Med J (2009) 0.86
Correlation between levels of N-terminal pro-B-type natriuretic peptide and degrees of heart failure. Korean J Intern Med (2005) 0.86
New antireflux self-expandable metal stent for malignant lower biliary obstruction: in vitro and in vivo preliminary study. Dig Endosc (2012) 0.86
Polymorphisms of thymidylate synthase gene 5'- and 3'-untranslated region and risk of gastric cancer in Koreans. Anticancer Res (2010) 0.85
Hepatitis A virus genotype and its correlation with the clinical outcome of acute hepatitis A in Korea: 2006-2008. J Med Virol (2011) 0.85
Clinical and echocardiographic predictors of outcomes in patients with apical hypertrophic cardiomyopathy. Am J Cardiol (2011) 0.85
Occult hepatitis B virus infection in pregnant woman and its clinical implication. Liver Int (2008) 0.85
The complete genome sequence and molecular analysis of human hepatitis E virus genotype IV identified from a Korean patient. Arch Virol (2010) 0.85
Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterol (2013) 0.84
Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population. Anticancer Res (2007) 0.84
Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy. J Gastroenterol (2010) 0.84
Fatal biliary-systemic air embolism during endoscopic retrograde cholangiopancreatography: a case with multifocal liver abscesses and choledochoduodenostomy. Yonsei Med J (2010) 0.84
Clinical characteristics of ischemic colitis according to location. J Korean Soc Coloproctol (2011) 0.84
A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis. Hepatogastroenterology (2012) 0.83
[A case of combined hepatocellular-cholangiocarcinoma with sarcomatous transformation and second primary colon cancer]. Korean J Hepatol (2004) 0.83
Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and patients with stomach cancer. Yonsei Med J (2008) 0.83
[Validation of the Korean version of liver disease quality of life (LDQOL 1.0) instrument]. Korean J Hepatol (2007) 0.83
Could a growth spurt cause linear focal elastosis like striae distensae? Ann Dermatol (2012) 0.82
Duodenal perforation after endoscopic hemoclip application for bleeding from Dieulafoy's lesion in a duodenal diverticulum. Gastrointest Endosc (2005) 0.82
The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy. Yonsei Med J (2011) 0.82
Associations of Expressions of HBcAg and HBsAg with the Histologic Activity of Liver Disease and Viral Replication. Gut Liver (2008) 0.82
[Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant]. Korean J Hepatol (2005) 0.82